OTCMKTS:HCYTD H-CYTE (HCYTD) Stock Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free HCYTD Stock Alerts $2.02 -1.98 (-49.50%) (As of 07/11/2022) Add Compare Share Share Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521,160.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get H-CYTE alerts: Email Address Ad Weiss RatingsMassive Crisis Looming — Protect Your Savings NowToday, Dr. Weiss is coming forward with a new warning, Only this time, it's not about the stock market, inflation, or recession … This time, it's about your financial freedom.Click here to learn how to prepare before it's too late. About H-CYTE Stock (OTCMKTS:HCYTD)H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Read More HCYTD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HCYTD Stock News HeadlinesJune 15 at 2:00 AM | americanbankingnews.comH-CYTE (OTCMKTS:HCYTD) vs. PolyPid (NASDAQ:PYPD) Head to Head ContrastMay 28, 2024 | finance.yahoo.comHydro One Limited (H.TO)May 25, 2024 | nytimes.comW.H. Hamilton Struck by a Train.April 12, 2024 | cbsnews.comThe best H&R Block DIY income tax filing options for last-minute filers in 2024March 1, 2024 | cnet.comH&R Block Review 2024: The Best Free Online Tax Filing ExperienceFebruary 14, 2024 | forbes.comH&R Block Coupons February 2024November 2, 2023 | morningstar.comHyatt Hotels Corp Class A HJune 14, 2023 | forbes.comH-E-B Grocery CompanyMay 12, 2023 | marketwatch.com10-K: H-CYTE, INC.March 24, 2023 | seekingalpha.comHCYT H-CYTE, Inc.September 8, 2022 | finance.yahoo.comH-CYTE Completes Acquisition of JantibodyJuly 23, 2022 | apnews.comH-CYTE to Expect the Completed Acquisition of Jantibody Within 30 DaysJune 13, 2022 | finance.yahoo.comH-CYTE Announces 1-for-1,000 Reverse Stock SplitMarch 6, 2022 | yahoo.comShould You Refrigerate Peanut Butter?March 6, 2022 | yahoo.comNetflix’s new superhero show might be the weirdest thing you ever watchMarch 4, 2022 | finance.yahoo.comH-CYTE Announces Proceeds of $1.05 Million from Warrant ExerciseFebruary 7, 2022 | nasdaq.comH-CYTE Inc (HCYT)January 11, 2022 | seekingalpha.comH-CYTE signs letter of intent to acquire Catheter PrecisionJanuary 11, 2022 | finance.yahoo.comH-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.December 6, 2021 | finance.yahoo.comH-CYTE Names Michael Yurkowsky Chief Executive OfficerSeptember 9, 2021 | au.finance.yahoo.comItalian court seeks opinion on Berlusconi's health due to trial delaysSeptember 8, 2021 | finance.yahoo.comH-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory HealthSee More Headlines Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolOTCMKTS:HCYTD CUSIPN/A CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,800,000.00 Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521,160.00 OptionableNot Optionable Beta1.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael W. Yurkowsky (Age 50)CEO & Director Comp: $180kMr. Jeremy Daniel (Age 46)Chief Financial Officer Comp: $200kDr. Tanya Rhodes Ph.D. (Age 61)Chief Scientific Officer Comp: $252kMr. Jeffery Wright CPA (Age 39)CPA, Controller & Principal Accounting Officer Key CompetitorsDynatronicsNASDAQ:DYNTNemaura MedicalNASDAQ:NMRDAethlon MedicalNASDAQ:AEMDAcutus MedicalNASDAQ:AFIBBluejay DiagnosticsNASDAQ:BJDXView All Competitors HCYTD Stock Analysis - Frequently Asked Questions How have HCYTD shares performed in 2024? H-CYTE's stock was trading at $2.02 on January 1st, 2024. Since then, HCYTD stock has increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2024 here. How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HCYTD) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share H-CYTE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.